Meeting
2021 ASCO Annual Meeting
ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).
Authors
Samuel J Klempner
Massachusetts General Hospital, Boston, MA
Samuel J Klempner , Liangliang Zhang , Ryon Graf , Russell Madison , Jeremy Snider , Cheryl D. Cho-Phan , Emily Castellanos , Gerald Li , Halla Nimeiri , Garrett M. Frampton , Geoffrey R. Oxnard , Jeffrey Michael Venstrom , Kimberly McGregor , Alexa Betzig Schrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4045)
DOI
10.1200/JCO.2021.39.15_suppl.4045
Abstract #
4045
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world comparison of treatment outcomes between advanced esophagogastric junction adenocarcinoma and gastric adenocarcinoma.
First Author: Toru Kadono
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.
First Author: Mary Frances Mulcahy
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
First Author: Toru Kadono
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price